MIT- and Harvard-linked researchers reported on 13 May that an mRNA-encoded adjuvant built from NIK and IRF8 boosted T-cell responses and eradicated most tumors in several mouse cancer models.
The study, published in Nature Biotechnology, used lipid nanoparticles to deliver immune-remodeling mRNAs that switch on antigen-presenting cells, the part of the immune system that tells T cells what to attack. That matters because many mRNA cancer vaccines fail in exactly the boring but fatal way you would expect: the immune system notices too little, too late.
Daniel Anderson, a professor in MIT’s Department of Chemical Engineering and a member of the Koch Institute for Integrative Cancer Research and the Institute for Medical Engineering and Science, and Christopher Garris, an assistant professor at Harvard Medical School and Massachusetts General Hospital, were the senior authors. The lead authors were Akash Gupta, now at the University of Houston, Kaelan Reed at MIT, and Riddha Das at Harvard Medical School and MGH.
The team packaged mRNAs encoding NF-κB-inducing kinase (NIK) or interferon regulatory factor 8 (IRF8) inside lipid nanoparticles. In the paper, these immune-remodeling mRNAs activated antigen-presenting cells in tumors, increased activated type 1 conventional dendritic cells, and primed antitumor CD8+ T cells. In plainer terms: instead of only giving the immune system a target, the researchers also tried to make it care.
“When these adjuvant mRNAs are included in the vaccines, the number of antigen-targeted T cells is substantially increased,” says Anderson.
In mice, the researchers tested the approach in aggressive bladder cancer, colon carcinoma, melanoma, and metastatic lung cancer. The paper says the treatment produced durable antitumor responses after both intratumoral and intravenous delivery, and MIT says most tumors were completely eradicated, either with the adjuvant on its own or combined with a tumor antigen.
The clearest quantitative result in the paper was from a vaccination experiment: co-administering the immune-remodeling mRNA with ovalbumin mRNA produced about a 10-fold increase in antigen-specific CD8+ T-cell responses and prevented tumor growth in vaccinated mice. The researchers also reported long-term immune memory, which is the part cancer immunotherapy papers like to promise and often struggle to show.
The effect was not limited to cancer models. In mice given influenza hemagglutinin mRNA alongside the adjuvant, the paper reports a roughly 5-fold increase in antibody responses and a roughly 15-fold increase in cellular responses. MIT’s writeup says similar T-cell gains were also seen with a Covid-19 vaccine.
Christopher Garris said in the MIT writeup that the immune-remodeling mRNAs help create a “T cell-permissive environment” in solid tumors. That is the central claim here: not just more vaccine, but a tumor environment less hostile to the cells meant to kill it.
There are two obvious caveats. First, this was a mouse study, and mouse tumors have a long history of being much easier to cure than human ones. Second, most of the public detail outside the paper comes from institutional writeups rather than independent reporting, so the hard numbers that matter most are the ones in the journal article.
The paper is titled “Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models” and appeared in Nature Biotechnology with DOI 10.1038/s41587-026-03115-2.
Key Takeaways
- MIT- and Harvard-linked researchers reported an mRNA adjuvant that boosted T-cell responses on 13 May 2026.
- The adjuvant used lipid nanoparticles to deliver mRNAs encoding NIK or IRF8.
- In mouse models of bladder cancer, colon carcinoma, melanoma, and metastatic lung cancer, most tumors were eradicated.
- Combining the adjuvant with ovalbumin mRNA increased antigen-specific CD8+ T-cell responses by about 10-fold.
- In an influenza vaccine experiment, the adjuvant increased antibody responses about 5-fold and cellular responses about 15-fold.
Further Reading
- A new approach to cancer vaccination yields more powerful T cells, MIT News writeup with named authors, quotes and the mouse-model summary.
- Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models, The primary Nature Biotechnology paper and DOI.
- Akash Gupta on T-cell cancer vaccine work, University of Houston follow-up tied to the lead author.
- MIT team develops mRNA adjuvant to boost T-cell response, Republished MIT account with the same core findings.
TOPIC VOCABULARY (from the research brief, may inform your keyword choice, but the article body is authoritative):
mRNA cancer vaccine, T-cell response, lipid nanoparticles, IRF8, NIK